Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

C mplete if Known					
Application Number	10/616,709				
Filing Date	July 10, 2003				
First Named Inv ntor	Neil P. Desai				
Group Art Unit	1614				
Examiner Name	Not yet assigned				
Attorney Docket Number	223416				

U.S. PATENT DOCUMENTS						
		U.S. Patent Docum	nent			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
RT	A1	5,439,686		Desai et al.	08/08/95	02/22/93
. [A2	5,498,421		Grinstaff et al.	03/12/96	02/22/94
	A3	5,560,933		Soon-Shiong et al.	10/01/96	03/29/95
	A4	5,637,625		Haynes	06/10/97	03/19/96
	A 5	5,665,382		Grinstaff et al.	09/09/97	06/07/95
	Α6	5,714,520		Jones et al.	02/03/98	03/22/95
	Α7	5,731,355		Jones et al.	03/24/98	02/18/97
	A 8	5,731,356		Jones et al.	03/24/98	02/18/97
	A 9	5,908,869		Jones et al.	06/01/99	01/30/98
	A10	5,916,596		Desai et al.	06/29/99	10/01/96
•	A11	5,962,536		Komer	10/05/99	07/31/98
	A12	6,028,108		George	02/22/00	10/22/98
	A 13	6,100,302		Pejaver et al.	08/08/00	04/05/99
	A14	6,140,373		May et al.	10/31/00	10/23/98
	A 1 5	6,147,122		Mirejovsky et al.	11/14/00	02/10/99
	A16	6,150,423		Carpenter	11/21/00	10/15/98
	A17	6,177,477		George et al.	01/23/01	03/24/99
	A18	6,326,406		De Tommaso	12/04/01	05/14/98
	A19	6,362,234		Hendler	03/26/02	08/15/00
	A20	6,399,087		Zhang et al.	06/04/02	12/20/00
	A21	6,469,069		Mirejovsky et al.	10/22/02	09/08/00

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Documer	nt			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
RT	B1		WO 94/18954		Clover Consolidated, Limited	09/01/94		
1	B2		WO 99/00113		Vivorx Pharmaceuticals, Inc.	01/07/99		
,								

		OTHER - NON PATENT LITERATURE DOCUMENTS	,	
Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Trans	lation
Initials	Initials No. (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		Yes	No⁴⁴

	Examiner Signature R. Teller	Date Considered 7/20/06
--	------------------------------	-------------------------

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plu	Is sign (+) Inside this box	→ [-	F OIPE 42	1		
	<u>-</u> 4		SEPVE		Complete if Known	
INFORMATION DISCLOSURE PAGE 18			P. C.	Spplication Number	10/616,709	
INFO	RMATION	DISC	I OSLIRE ADEND	Filing Date	July 10, 2003	
STA	TEMENT BY	/ AD	DUCANT	First Named Inventor	Desai et al.	
314	I CIMICIAL D	AF	PLICANI	Group Art Unit	1654	
	(Use as many sheet	s as ne	cessary)	Examiner Name	Teller, Róy R.	
Sheet	1	of	1	Attorney Docket Number	223416	

				U.S. PATENT DOCUMENTS		
		U.S. Patent Do	cument			
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
RT	AA	2002/0006442	A1	Mishra et al.	Jan. 17, 2002	
	<u> </u>					
			ļ <u> </u>			
			 		_	
	 -	•	<u> </u>			
	L	L				

				FORE	IGN PATENT DOCUMENTS	•		
		Foreign Patent Document		nt			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
RT	AB	EP	0 390 244	A1	Duphar International Research B.V.	Oct. 3, 1990		
	AC	WO	01/64187	A2	Maelor Pharmaceuticals Limited	Sep. 7, 2001		
	ΑD	WO	02/45709	A1	Bharat Serums & Vaccines Ltd.	Jun. 13, 2002		
	AE	wo	04/052401	A2	American BioSciences, Inc.	Jun. 24, 2004		†
		L						

		OTHER - NON PATENT LITERATURE DOCUMENTS	_		
Examiner Doc.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher,			
	NO.	city and/or country where published.	Yes	No⊶	
RT	AF	BAUER et al., Pharmazeutische Technologie,: 256-257 (1986)		х	
	AG	FARINOTTI, Annales Françaises d'Anesthesie et de Reanimation., 13: 453-456 (1994)		X*	
	AH	JONES, Anaesthesia and Intensive Care, 28(5): 587 (October 2000)		 ^	
	ΑI	NAGUIB et al., Anesthesiology Abstracts of Scientific Papers Annual Meeting,: 1 (October 13, 2003)			
	AJ	SAUTOU-MIRANDA et al., International Journal of Pharmaceutics, 130(2): 251-255 (1996)			
	AK	TRAPANI et al., International Journal of Pharmaceutics, 278(1): 91-98 (June 18, 2004)		\vdash	
	AL	West Furotec Barrier Film,: 1-2 (December 3, 2003) [http://web.archive.org/web/20031203023630/http://www.westpharma.com/products/flurotec.asp]			

Consider Oil			
Examiner Signature	2 T 00	Date Considered	
_	K. I eller	Date Considered	7/20/06
	1. 900 (11~106

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).